Lord, Abbett & Co
RARE icon

Lord, Abbett & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

Lord, Abbett & Co’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-324,724
Closed -$19.4M – 607
2022
Q2 		$19.4M Buy
324,724
+10,980
+3% +$676K 0.07% 337
2022
Q1 		$22.8M Buy
313,744
+63
+0% +$4.38K 0.06% 355
2021
Q4 		$26.4M Sell
313,681
-116,225
-27% -$9.46M 0.06% 362
2021
Q3 		$38.8M Buy
429,906
+65,097
+18% +$5.88M 0.09% 318
2021
Q2 		$34.8M Sell
364,809
-13,017
-3% -$1.36M 0.08% 330
2021
Q1 		$43M Buy
+377,826
New +$51.4M 0.11% 292
2018
Q4 		– Sell
-273,479
Closed -$20.9M – 816
2018
Q3 		$20.9M Buy
+273,479
New +$22.2M 0.06% 469
2016
Q4 		– Sell
-157,176
Closed -$11.2M – 941
2016
Q3 		$11.2M Sell
157,176
-179,977
-53% -$11.5M 0.03% 547
2016
Q2 		$16.5M Buy
337,153
+181,270
+116% +$11.7M 0.05% 454
2016
Q1 		$9.87M Sell
155,883
-123,830
-44% -$8.1M 0.03% 575
2015
Q4 		$31.4M Buy
279,713
+48,133
+21% +$4.81M 0.09% 332
2015
Q3 		$22.3M Sell
231,580
-496,079
-68% -$56.8M 0.07% 389
2015
Q2 		$74.5M Buy
727,659
+99,327
+16% +$7.71M 0.2% 139
2015
Q1 		$39M Buy
628,332
+200,916
+47% +$11.2M 0.1% 320
2014
Q4 		$18.8M Sell
427,416
-150,215
-26% -$6.88M 0.05% 481
2014
Q3 		$32.7M Buy
577,631
+345,765
+149% +$17.4M 0.08% 343
2014
Q2 		$10.4M Buy
231,866
+177,722
+328% +$7.32M 0.02% 632
2014
Q1 		$2.65M Buy
+54,144
New +$2.79M 0.01% 896

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Lord, Abbett & Co's RARE Position: Q3 2022 in Review

Lord, Abbett & Co sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2022, closing a stake of 324,724 shares — an estimated $19.4M sold.

Lord, Abbett & Co first reported a position in RARE in Q1 2014 and held it in 18 quarters. The position peaked at $74.5M in Q2 2015. 232 funds tracked by Wall St. Rank hold RARE as of Q3 2022.

  • Lord, Abbett & Co reported no remaining Ultragenyx Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • Lord, Abbett & Co sold 324,724 Ultragenyx Pharmaceutical shares in Q3 2022, an estimated $19.4M.
  • Lord, Abbett & Co first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 18 quarters.
  • Lord, Abbett & Co's Ultragenyx Pharmaceutical position peaked at $74.5M in Q2 2015.
  • 232 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2022.

Based on Lord, Abbett & Co's 13F filing for Q3 2022, filed 14 Nov 2022.